OncoMatch/Clinical Trials/NCT07680933
Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
Is NCT07680933 recruiting? Yes, currently enrolling (Jul 2026). This Phase 2 trial studies Orelabrutinib combined with standard immunochemotherapy with or without auto-HSCT for dlbcl - diffuse large b cell lymphoma.
Treatment: Orelabrutinib combined with standard immunochemotherapy with or without auto-HSCT — This study is a prospective, open-label, multicenter study in previously untreated participants with CD20-positive DLBCL. Orelabrutinib combined with standard immunochemotherapy with or without autologous hematopoietic stem cell transplantation (auto-HSCT) for newly diagnosed diffuse large B-cell lymphoma (DLBCL). The primary objective is to explore the 1-year progression-free survival (PFS) of orelabrutinib combined with standard immunochemotherapy with or without auto-HSCT in newly diagnosed DLBCL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 expression
Pathologically confirmed CD20-positive DLBCL
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Blood counts
Hemoglobin ≥90 g/L within 7 days prior to enrollment without packed red blood cell transfusion; ANC ≥1.0 × 10⁹/L; Platelet count ≥75 × 10⁹/L
Kidney function
Creatinine ≤ 1.5× ULN; creatinine clearance ≥ 60 mL/min (estimated by Cockcroft-Gault formula)
Liver function
ALT or AST ≤ 2× ULN; ALP and bilirubin ≤ 1.5× ULN
Cardiac function
Left ventricular ejection fraction (LVEF) ≥50% as assessed by MUGA scan or ECHO
Adequate hematologic function...Hemoglobin ≥90 g/L...ANC ≥1.0 × 10⁹/L; Platelet count ≥75 × 10⁹/L. Adequate organ function. LVEF ≥50% as assessed by MUGA scan or ECHO
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07680933 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require MS4A1?
Yes, MS4A1 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify